1. Home
  2. PHAR vs NDMO Comparison

PHAR vs NDMO Comparison

Compare PHAR & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • NDMO
  • Stock Information
  • Founded
  • PHAR 1988
  • NDMO 2019
  • Country
  • PHAR Netherlands
  • NDMO United States
  • Employees
  • PHAR N/A
  • NDMO N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • NDMO Trusts Except Educational Religious and Charitable
  • Sector
  • PHAR Health Care
  • NDMO Finance
  • Exchange
  • PHAR Nasdaq
  • NDMO Nasdaq
  • Market Cap
  • PHAR 679.0M
  • NDMO 596.2M
  • IPO Year
  • PHAR N/A
  • NDMO N/A
  • Fundamental
  • Price
  • PHAR $9.13
  • NDMO $10.38
  • Analyst Decision
  • PHAR Strong Buy
  • NDMO
  • Analyst Count
  • PHAR 3
  • NDMO 0
  • Target Price
  • PHAR $27.00
  • NDMO N/A
  • AVG Volume (30 Days)
  • PHAR 5.4K
  • NDMO 218.6K
  • Earning Date
  • PHAR 03-13-2025
  • NDMO 01-01-0001
  • Dividend Yield
  • PHAR N/A
  • NDMO 6.75%
  • EPS Growth
  • PHAR N/A
  • NDMO N/A
  • EPS
  • PHAR N/A
  • NDMO N/A
  • Revenue
  • PHAR $285,745,000.00
  • NDMO N/A
  • Revenue This Year
  • PHAR $20.08
  • NDMO N/A
  • Revenue Next Year
  • PHAR $9.22
  • NDMO N/A
  • P/E Ratio
  • PHAR N/A
  • NDMO N/A
  • Revenue Growth
  • PHAR 30.64
  • NDMO N/A
  • 52 Week Low
  • PHAR $6.65
  • NDMO $8.99
  • 52 Week High
  • PHAR $13.20
  • NDMO $11.24
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 50.97
  • NDMO 57.64
  • Support Level
  • PHAR $9.37
  • NDMO $10.08
  • Resistance Level
  • PHAR $10.01
  • NDMO $10.40
  • Average True Range (ATR)
  • PHAR 0.47
  • NDMO 0.09
  • MACD
  • PHAR -0.10
  • NDMO 0.05
  • Stochastic Oscillator
  • PHAR 28.08
  • NDMO 93.75

About PHAR Pharming Group N.V.

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.

Share on Social Networks: